Antibody-Mediated Rejection in a Multiple Lung Transplant Patient: A Case Report

• Published in: Transplantation proceedings Vol. 51; no. 4; pp. 1296 - 1298
• Main Authors: Radeczky, P., Ghimessy, Á.K., Farkas, A., Csende, K., Mészáros, L., Török, K., Fazekas, L., Agócs, L., Kocsis, Á., Bartók, T., Dancs, T., Tóth, K.K., Schönauer, N., Bogyó, L., Bohács, A., Madurka, I., Elek, J., Döme, B., Rényi-Vámos, F., Lang, G., Gieszer, B.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2019
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2019.03.005

Lung transplant is an effective way to treat many end-stage lung diseases. However, one of the main barriers of allograft organ transplant is still the immunologic rejection of transplanted tissue, which is a response of the HLA molecules. Rejection is a complex process involving both T-cell–mediated delayed-type hypersensitivity reactions and antibody-mediated hypersensitivity reactions to histocompatibility molecules on foreign grafts. We report the case of a 25-year-old female patient with cystic fibrosis who underwent 2 lung transplants because of her initial diagnosis and appearance of bronchiolitis obliterans syndrome after the first transplant. Only 13 months after the second transplant, despite the therapies applied, a new rejection occurred associated with high mean fluorescent intensity donor-specific antibody levels, which resulted later in the death of the patient. The present case draws attention to the importance of matching HLA molecules between donor and recipient in addition to immunosuppressive therapy.